Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.

Amler, L C; Goddard, A D; Hillan, K J

Amler, L C; Goddard, A D; Hillan, K J.

Affiliation

Amler LC; Development Sciences, Genentech, Inc., South San Francisco, California 94080, USA.

Cold Spring Harb Symp Quant Biol ; 70: 483-8, 2005.

Article in En | MEDLINE | ID: mdl-16869787

Subject(s)

Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/enzymology; ErbB Receptors/antagonists & inhibitors; Lung Neoplasms/drug therapy; Lung Neoplasms/enzymology; Protein Kinase Inhibitors/therapeutic use; Carcinoma, Non-Small-Cell Lung/genetics; ErbB Receptors/genetics; ErbB Receptors/metabolism; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms/genetics; Mutation; Prognosis; Quinazolines/therapeutic use; Signal Transduction; Smoking/adverse effects; Smoking/genetics

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / ErbB Receptors / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cold Spring Harb Symp Quant Biol Year: 2005 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links